From 09ddb4b5a6c40a73f2948c7f294dbacecb10a870 Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Tue, 20 Feb 2024 11:41:07 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web___Update 2024___02.md | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) diff --git a/pages/STOP2030___Web___Update 2024___02.md b/pages/STOP2030___Web___Update 2024___02.md index aa5b39af..c7d64c78 100644 --- a/pages/STOP2030___Web___Update 2024___02.md +++ b/pages/STOP2030___Web___Update 2024___02.md @@ -86,4 +86,5 @@ - ### Background - Especificar que la novel formulation es una fixed-dose coformulation de [[Ivermectina]] y [[Albendazol]]. - Especificar que esta fixed-dose coformulation de ivm/alb has the lowest [[level]] of investment risk of all candidates for Combinations for [[STH]] treatment (fuente: Soil Transmitted Helminths Drug Combinations Expert Meeting, 2016, Gates Foundation) - - El ALIVE study \ No newline at end of file + - El ALIVE trial study: https://gatesopenresearch.org/articles/6-62/v1 + - \ No newline at end of file